Core Viewpoint - The company, 来凯医药-B (02105), has initiated a Phase I multi-dose expansion study for LAE102, aimed at treating obesity, with the first subject having been dosed [1] Group 1: Study Details - The Phase I multi-dose expansion study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102 in 60 overweight/obese subjects [1] - Subjects will be randomly assigned to either the LAE102 group or the placebo group, receiving treatment for a duration of 6 months [1] - The study is based on previously observed positive one-month treatment results from an earlier MAD study, aiming to further assess the efficacy and safety characteristics after prolonged treatment [1] Group 2: Company Commitment - The company is dedicated to providing precision treatment options for patients suffering from obesity or metabolic diseases who require new therapeutic alternatives [1]
来凯医药-B(02105)：LAE102针对治疗肥胖症的I期多剂量扩展研究完成首例受试者给药